{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T13:53:50Z","timestamp":1721397230110},"reference-count":30,"publisher":"Institute of Physiology of the Czech Academy of Sciences","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Physiol Res"],"published-print":{"date-parts":[[2014,12,31]]},"abstract":"<jats:p>Acetylcholinesterase inhibitors (AChEIs) are used in the treatment of myasthenia gravis (MG). We investigated the effects of AChEIs on peripheral nicotinic receptors (nAChR), which play a crucial role in the treatment of MG symptoms. The positive modulation of those receptors by AChE inhibitors could have an added value to the anti-AChE activity and might be useful in the therapy of MG. Furthermore, to estimate the potential drawbacks of the compounds, cytotoxicity has been assessed on various cell lines. The whole-cell mode of the patch-clamp method was employed. The experiments were performed on medulloblastoma\/rhabdomyosarcoma cell line TE671 expressing human embryonic muscle-like receptor with subunits \u03b12\u03b2\u03b3\u03b4. The effect of the compounds on cell viability was measured by standard MTT assay (Sigma Aldrich) on ACHN (renal cell adenocarcinoma), HeLa (immortal cell line derived from a cervical carcinoma), HEPG2 (hepatocellular carcinoma) and BJ (skin fibroblasts) cell lines. No positive modulation by the tested AChE inhibitors was observed. Moreover, the compounds exhibited antagonistic activity on the peripheral nAChR. Standard drugs used in MG treatment were shown to be less potent inhibitors of muscle-type nAChR than the newly synthesized compounds. The new compounds showed very little effect on cell viability, and toxicities were comparable to standards. Newly synthesized AChEIs inhibited peripheral nAChR. Furthermore, the inhibition was higher than that of standards used for the treatment of MG. They could be used for the study of nAChR function, thanks to their high antagonizing potency and fast recovery of receptor activity after their removal. However, since no positive modulation was observed, the new compounds do not seem to be promising candidates for MG treatment, even though their cytotoxic effect was relatively low.<\/jats:p>","DOI":"10.33549\/physiolres.932768","type":"journal-article","created":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T17:50:41Z","timestamp":1607536241000},"page":"771-777","source":"Crossref","is-referenced-by-count":6,"title":["The Interaction of Quaternary Reversible Acetylcholinesterase Inhibitors With the Nicotinic Receptor"],"prefix":"10.33549","author":[{"given":"V.","family":"SEPSOVA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"KRUSEK","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"ZDAROVA KARASOVA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"ZEMEK","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"MUSILEK","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"KUCA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"SOUKUP","sequence":"additional","affiliation":[{"name":"Biomedical Research Center, University Hospital Hradec Kralove, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"19169","published-online":{"date-parts":[[2014,12,17]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"ARIAS HR: Localization of agonist and competitive antagonist binding sites on nicotinic acetylcholine receptors. Neurochem Int 36: 595-645, 2000.","DOI":"10.1016\/s0197-0186(99)00154-0"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"ASTLES PC, BAKER SR, BOOT JR, BROAD LM, DELL CP, KEENAN M: Recent progress in the development of subtype selective nicotinic acetylcholine receptor ligands. Curr Drug Targets CNS Neuro Disord 1: 337-348, 2002.","DOI":"10.2174\/1568007023339256"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"BROAD LM, ZWART R, PEARSON KH, LEE M, WALLACE L, MCPHIE GI, EMKEY R, HOLLINSHEAD SP, DELL CP, BAKER SR, SHER E: Identification and pharmacological profile of a new class of selective nicotinic acetylcholine receptor potentiators. J Pharmacol Exp Ther 318: 1108-1117, 2006.","DOI":"10.1124\/jpet.106.104505"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"CANTI C, BODAS E, MARSAL J, SOLSONA C: Tacrine and physostigmine block nicotinic receptors in Xenopus oocytes injected with Torpedo electroplaque membranes. Eur J Pharmacol 363: 197-202, 1998.","DOI":"10.1016\/s0014-2999(98)00793-6"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"COLOMBO SF, MAZZO F, PISTILLO F, GOTTI C: Biogenesis, trafficking and up-regulation of nicotinic ACh recepors. Biochem Pharmacol 86: 1063-1073, 2013.","DOI":"10.1016\/j.bcp.2013.06.023"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"DITTERT I, VLACHOVA V, KNOTKOVA H, VITASKOVA Z, VYKLICKY L, KRESS M, REEH PW: A technique for fast application of heated solutions of different composition to cultured neurones. J Neurosci Methods 82: 195-201, 1998.","DOI":"10.1016\/s0165-0270(98)00051-x"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"GORELICK DA: Enhancing cocaine metabolism with butyrylcholinesterase as a treatment strategy. Drug Alcohol Depend 48: 159-165, 1997.","DOI":"10.1016\/s0376-8716(97)00119-1"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"GOTTI C, CLEMENTI F: Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol 74: 363-396, 2004.","DOI":"10.1016\/j.pneurobio.2004.09.006"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"HOGG RC, BUISSON B, BERTRAND D: Allosteric modulation of ligand-gated ion channels. Biochem Pharmacol 70: 1267-1276, 2005.","DOI":"10.1016\/j.bcp.2005.06.010"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"JUN D, KUCA K, STODULKA P, KOLECKAR V, DOLEZAL B, SIMON P, VEVERKA M: HPLC analysis of HI-6 dichloride and dimethansulfonate \u2013 antidotes against nerve agents and organophosphorus pesticides. Anal Lett 40: 2783-2787, 2007.","DOI":"10.1080\/00032710701588531"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"JUN D, STODULKA P, KUCA K, KOLECKAR V, DOLEZAL B, SIMON P, VEVERKA M: TLC analysis of intermediates arising during the preparation of oxime HI-6 dimethylsulfonate. J Chrom Sci 46: 316-319, 2008.","DOI":"10.1093\/chromsci\/46.4.316"},{"key":"ref11","unstructured":"KE L, EISENHOUR CM, BENCHERIF M, LUKAS RJ: Effects of chronic nicotine treatment on expression of diverse nicotinic acetylcholine receptor subtypes. I. Dose- and time-dependent effects of nicotine treatment. J Pharmacol Exp Ther 286: 825-840, 1998."},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"KOMLOOVA M, MUSILEK K, KUCA K: Myasthenia gravis - current treatment standards and emerging drugs (in Czech). Ceska Slov Farm 60: 47-53, 2011a.","DOI":"10.5772\/31127"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"KOMLOOVA M, MUSILEK K, HOROVA A, HOLAS O, DOHNAL V, GUNN-MOORE F, KUCA K: Preparation, in vitro screening and molecular modelling of symetrical bis-quinolinium cholinesterase inhibitors - implications for early Myasthenia gravis treatment. Bioorg Med Chem Lett 21: 2505-2509, 2011b.","DOI":"10.1016\/j.bmcl.2011.02.047"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"KUMAR V, KAMINSKI HJ: Treatment of myasthenia gravis. Curr Neurol Neurosci Rep 11: 89-96, 2011.","DOI":"10.1007\/s11910-010-0151-1"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"LESTER HA, DIBAS MI, DAHAN DS, LEITE JF, DOUGHERTY DA: Cysloop receptors: new twists and turns. Trends Neurosci 27: 329-336, 2004.","DOI":"10.1016\/j.tins.2004.04.002"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"LINDOVSKY J, PETROV K, KRUSEK J, REZNIK VS, NIKOLSKY EE, VYSKOCIL F: Effect of tissue-specific acetylcholinesterase inhibitor C-547 on \u03b13\u03b24 and \u03b1\u03b2\u03b5\u03b4 acetylcholine receptors in COS cells. Eur J Pharmacol 688: 22-26, 2012.","DOI":"10.1016\/j.ejphar.2012.05.010"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"MAELICKE A, ALBUQUERQUE EX: Alosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer\u2019s disease. Eur J Pharmacol 393: 165-170, 2000.","DOI":"10.1016\/s0014-2999(00)00093-5"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"MAYER ML, VYKLICKY L: Concanavalin A selectively reduces desensitization of mammalian neuronal quisqualate receptors. Proc Nat Acad Sci USA 86: 1411-1415, 1989.","DOI":"10.1073\/pnas.86.4.1411"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"MUSILEK K, KOMLOOVA M, HOLAS O, HRABINOVA M, POHANKA M, DOHNAL V, NACHON F, DOLEZAL M, KUCA K: Preparation and in vitro screening of symmetrical bis-isoquinolinium cholinesterase inhibitors bearing various connecting linkage \u2013 implications for early Myasthenia gravis treatment. Eur J Med Chem 46: 811, 2011.","DOI":"10.1016\/j.ejmech.2010.12.011"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"OLIVERA-BRAVO S, IVORRA I, MORALES A: Diverse inhibitory actions of quarternary ammonium cholinesterase inhibitors on Torpedo nicotinic ACh receptors transplanted to Xenopus oocytes. Brit J Pharmacol 151: 1280-1292, 2007.","DOI":"10.1038\/sj.bjp.0707329"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"PEREIRA EF, HILMAS C, SANTOS MD, ALKONDON M, MAEILICKE A, ALBUQUERQUE EX: Unconventional ligands and modulators of nicotinic receptors. J Neurobiol 53: 479-500, 2002.","DOI":"10.1002\/neu.10146"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"SCHERER K, BEDLACK RS, SIMEL DL: Does this patient have myasthenia gravis? JAMA 20: 1906-1914, 2005.","DOI":"10.1001\/jama.293.15.1906"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"SCHOEPFER R, LUTHER M, LINDSTROM J: The human medulloblastom cell line TE671 expresses a muscle-like acetylcholine receptor. Cloning of the alpha-subunit c DNA. FEBS Lett 226: 235-240, 1988.","DOI":"10.1016\/0014-5793(88)81430-3"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"SOUKUP O, KRUSEK J, KANIAKOVA M, KUMAR UK, OZ M, JUN D, FUSEK J, KUCA K, TOBIN G: Oxime reactivators and their in vivo and in vitro effects on nicotinic receptors. Physiol Res 60: 679-686, 2011.","DOI":"10.33549\/physiolres.932105"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"SOUKUP O, JUN D, TOBIN G, KUCA K: The summary on non-reactivation cholinergic properties of oxime reactivators: the interaction with muscarinic and nicotinic receptors. Arch Toxicol 87: 711-719, 2013a.","DOI":"10.1007\/s00204-012-0977-1"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"SOUKUP O, JUN D, ZDAROVA-KARASOVA J, PATOCKA J, MUSILEK K, KORABECNY J, KRUSEK J, KANIAKOVA M, SEPSOVA V, MANDIKOVA J, TREJTNAR F, POHANKA M, DRTINOVA L, PAVLIK M, TOBIN G, KUCA K: A resurrection of 7-MEOTA: a comparison with tacrine. Curr Alz Res 10: 893-906, 2013b.","DOI":"10.2174\/1567205011310080011"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"STRATTON MR, DARLING J, PILKINGTON GJ, LANTOS PL, REEVES BR, COOPER CS: Characterization of the human cell line TE671. Carcinogenesis 10: 899-905, 1989.","DOI":"10.1093\/carcin\/10.5.899"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"TURNER C: A review of myasthenia gravis: Pathogenesis, clinical features and treatment. Curr Anaesth Crit Care 18: 15-23, 2007.","DOI":"10.1016\/j.cacc.2007.01.006"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"YOST CS, MAESTRONE E: Clinical concentrations of Edrophonium enhance desensitization of the nicotinic acetylcholine receptor. Anesth Analg 78: 520-526, 1994.","DOI":"10.1213\/00000539-199403000-00018"}],"container-title":["Physiological Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T18:50:01Z","timestamp":1607539801000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.biomed.cas.cz\/physiolres\/pdf\/63\/63_771.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,17]]},"references-count":30,"URL":"https:\/\/doi.org\/10.33549\/physiolres.932768","relation":{},"ISSN":["1802-9973","0862-8408"],"issn-type":[{"value":"1802-9973","type":"electronic"},{"value":"0862-8408","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12,17]]}}}